<DOC>
	<DOCNO>NCT02808312</DOCNO>
	<brief_summary>The primary objective study evaluate single-dose pharmacokinetics GS-9674 adult impair hepatic function relative match , healthy control normal hepatic function .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics GS-9674 Adults With Normal Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Cohort 1 : Individuals mildly impair normal hepatic function . Individuals mild hepatic impairment must score 56 CPT Classification Screening without evidence worsen clinical and/or laboratory sign hepatic impairment within 2 month prior within screen period . Cohort 2 : Individuals moderately impair normal hepatic function . Individuals moderate hepatic impairment must score 79 CPT Classification Screening without evidence worsen clinical and/or laboratory sign hepatic impairment within 2 month prior within screen period . Cohort 3 : Individuals severely impair normal hepatic function . Individuals severe hepatic impairment must score 1015 CPT Classification Screening without evidence worsen clinical and/or laboratory sign hepatic impairment within 2 month prior within screen period . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>